PEN Earnings Date: Nov 4, 2026 (Estimated) — Penumbra, Inc.
NYSE · Healthcare · Medical Devices
Updated
When is PEN's next earnings date?
Penumbra, Inc. (PEN) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.20 on revenue of $401.4M.
How did PEN do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Penumbra, Inc. posted EPS of $0.88 versus the $1.18 estimate, a miss of 25.4%. Revenue was $390.0M against a $388.9M estimate. The stock's 1-day post-earnings move was +0.4%.
How much does PEN stock move after earnings?
PEN beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.7% (up or down) in the day after earnings.
About Penumbra, Inc.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | 1.18 | 0.88 | -25.42% | $390.0M | ❌ Miss | +0.43% | +1.57% | +0.58% |
| 2026-05-06 | Q1 2026 | 1.07 | 1.00 | -6.07% | $374.8M | ❌ Miss | +0.14% | -0.49% | -1.13% |
| 2026-02-25 | Q4 2025 | 1.12 | 1.18 | +5.36% | $385.4M | ✅ Beat | +0.97% | +0.28% | -0.66% |
| 2025-11-05 | Q3 2025 | 0.91 | 0.97 | +6.59% | $354.7M | ✅ Beat | +17.32% | +24.28% | +33.31% |
| 2025-07-29 | Q2 2025 | 0.82 | 0.86 | — | $339.5M | ✅ Beat | +11.91% | +5.70% | +17.51% |
| 2025-04-23 | Q1 2025 | 0.67 | 0.83 | +23.88% | $324.1M | ✅ Beat | +6.99% | +5.05% | -4.31% |
| 2025-02-18 | Q4 2024 | 0.89 | 0.97 | +8.99% | $315.5M | ✅ Beat | +12.03% | +3.87% | +3.08% |
| 2024-07-30 | Q2 2024 | 0.56 | 0.64 | +14.29% | $299.4M | ✅ Beat | -3.47% | -0.95% | +15.81% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY23 · $270.9M total
| Segment | Share | Revenue | YoY | Q1 FY22 | Q2 FY22 | Q3 FY22 | Q4 FY22 |
|---|---|---|---|---|---|---|---|
| Neuro | 63.3% | $171.4M | +89.8% | $81.1M | $84.8M | $90.3M | $91.5M |
| Peripheral Vascular | 36.7% | $99.5M | -19.3% | $122.8M | $123.5M | $123.4M | $129.7M |
By region
Q3 FY26 · $410.1M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 79.1% | $324.2M | +17.9% | $256.9M | $260.8M | $275.0M | $299.1M |
| Non-US | 20.9% | $85.9M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.